Ovarian Cancer

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the rationale behind the TOPACIO trial for the treatment of patients with recurrent ovarian cancer.

Ursula A. Matulonis, MD, chief, Division of Gynecological Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the rationale behind the QUADRA trial for patients with relapsed ovarian cancer.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses the latest advances in treatment for gynecological malignancies and other tumor types.

Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses second-line maintenance therapy after frontline chemotherapy for patients with ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses resistance to PARP inhibitors in ovarian cancer.

Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses pain management in patients with ovarian cancer.

Deborah Krakow, MD, discusses the value of a patient’s family history and its implications on genetic counseling.

Christopher J. Pietras, MD, discusses the elements of palliative care for patients with ovarian cancer.

Sanaz Memarzadeh, MD, PhD, details the early developments of antibody-directed therapies and restoring p53 function in the treatment of patients with ovarian cancer.

Gottfried E. Konecny, MD, discusses developments in the understanding of response to PARP inhibition in ovarian cancer.

John A. Glaspy, MD, discusses challenges and progress with immunotherapy in gynecologic cancers.

Dennis J. Slamon, MD, PhD, discusses new opportunities for treatment advances in ovarian cancer.

Kelly McCann, MD, PhD, discusses the process of DNA damage and repair, resistance to PARP inhibitors, and rational combination strategies to overcome resistance.

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses testing for somatic and germline mutations in patients with ovarian cancer.

Olaparib tablets reduced the risk of disease progression or death compared with placebo as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.

Ovarian cancer incidence and mortality have declined significantly over the past few decades, but eliminating racial disparities in treatment and improving prevention and early detection could help save even more women.

Joshua P. Sasine, MD, medical director, Chimeric Antigen Receptor T-Cell Program, David Geffen School of Medicine, University of California, Los Angeles, discusses chimeric antigen receptor (CAR) T- cell therapy in ovarian cancer.

The FDA has approved bevacizumab for use in combination with carboplatin and paclitaxel, followed by bevacizumab monotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the FDA approval of bevacizumab (Avastin) as a frontline treatment in combination with carboplatin and paclitaxel, followed by bevacizumab alone, for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.